入组标准:1肿瘤-淋巴结-转移(tumor-node-metastasis, TNM)分期标准采用国际肺癌研究协会(International Association for the Study of Lung Cancer, IASLC)2017年第七版分期标准,根据TNM分期证实的III期和IV期表皮生长因子受体(epidermal growth factor receptor, EGFR)、鼠类肉瘤病毒癌基因(kirsten rat sarcoma viral oncogene, KRAS)、鼠类肉瘤滤过性毒菌致癌同源体B1(V-rafmurine sarcoma viral oncogene homolog B1, BRAF)均为阴性的NSCLC患者,初治选用培美曲塞联合铂类的一线双药化疗;2化疗期间未同步或序贯接受放疗或其他相关抗肿瘤治疗;3既往未接受过手术、放射治疗;4根据实体瘤疗效评价标准(Response Evaluation Criteria in Solid Tumors, RECIST)1.1[8]至少有1个可测量的病灶,定期复查计算机断层扫描(computed tomography, CT)评价疗效。. The gene discussed is EGFR; the disease is lung carcinoma.